XML 75 R2.htm IDEA: XBRL DOCUMENT v3.19.3
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 1,241 $ 1,782
Trade receivables 5,254 5,822
Inventories 4,636 4,731
Prepaid expenses 976 899
Other current assets 416 468
Assets held for sale 18 92
Total current assets 12,542 13,794
Deferred income taxes 331 368
Other non-current assets 727 731
Property, plant and equipment, net 6,643 6,868
Operating lease right-of-use assets 468  
Identifiable intangible assets, net 11,878 14,005
Goodwill [1] 24,657 24,917
Total assets 57,246 60,683
Current liabilities:    
Short-term debt 3,130 2,216
Sales reserves and allowances 6,137 6,711
Trade payables 1,688 1,853
Employee-related obligations 583 870
Accrued expenses 1,748 1,868
Other current liabilities 820 804
Total current liabilities 14,107 14,322
Long-term liabilities:    
Deferred income taxes 1,462 2,140
Other taxes and long-term liabilities 2,546 1,727
Senior notes and loans 23,812 26,700
Operating lease liabilities 394  
Total long-term liabilities 28,215 30,567
Commitments and contingencies, see note 16
Total liabilities 42,322 44,889
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; September 30, 2019 and December 31, 2018: authorized 2,495 million shares; issued 1,198 million shares and 1,196 million shares, respectively 56 56
Additional paid-in capital 27,293 27,210
Accumulated deficit (7,066) (5,958)
Accumulated other comprehensive loss (2,365) (2,459)
Treasury shares as of September 30, 2019 and December 31, 2018 — 106 million ordinary shares (4,128) (4,142)
Stockholders' equity attributable to Teva shareholders 13,790 14,707
Non-controlling interests 1,134 1,087
Total equity 14,925 15,794
Total liabilities and equity $ 57,246 $ 60,683
[1] Accumulated goodwill impairment as of September 30, 2019 and January 1, 2019 was approximately $21.0 billion.